Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study

BACKGROUND: HMS5552, a novel fourth-generation glucokinase (GK) activator, has demonstrated promising effects on glycemic control in preclinical models of type 2 diabetes. This single ascending dose study was conducted to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynam...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Drug Des Devel Ther
Asıl Yazarlar: Xu, Hongrong, Sheng, Lei, Chen, Weili, Yuan, Fei, Yang, Mengjie, Li, Hui, Li, Xuening, Choi, John, Zhao, Guiyu, Hu, Tianxin, Li, Yongguo, Zhang, Yi, Chen, Li
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2016
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4869670/
https://ncbi.nlm.nih.gov/pubmed/27274195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S105021
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller